home All News open_in_new Full Article

Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology Lecanemab is the first therapy that targets an underlying cause […]


today 3 d. ago attach_file Economics

attach_file Economics
attach_file Economics
attach_file Economics
attach_file Transport
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Economics


ID: 2714400091
Add Watch Country

arrow_drop_down